Principal Investigator for ACCORD Trial Continues Research in Glycemia Reduction Approaches in Diabetes – A Comparative Effectiveness Study (GRADE)

December 20, 2015

Clinical & Molecular Endocrinology – January 2016 - View Full PDF

Faramarz Ismail-Beigi, MD, PhD

Clinical and Molecular Endocrinology, UH Case Medical Center; Professor of Medicine, Case Western Reserve University School of Medicine

Faramarz Ismail-Beigi, MD was a principal investigator on the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, which found that intensively targeting blood sugar in adults with type 2 diabetes who are also at high risk for heart attack and stroke does not significantly reduce the risk of major cardiovascular events, but does increase risk of death compared with standard treatment.

Building on these findings, the Action to Control Cardiovascular Risk in Diabetes Follow On (ACCORDION) clinical trial is an observational study of at least 8,000 participants of the ACCORD trial, which ended in 2009. ACCORDION is designed to further research the long-term effects of the ACCORD treatment strategies and the relationships among various cardiovascular and diabetic risk factors. Dr. Ismail-Beigi is currently leading a new NIH-sponsored clinical trial, The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). It is a long-term study of different treatments for type 2 diabetes.

To learn more about the ACCORD research, contact Dr. Ismail-Beigi at


All National Institutes of Health (NIH) funding for basic and clinical research is awarded to the School of Medicine at Case Western Reserve University

Important Links & Numbers

Refer A Patient

Call Direct 866-UH4-CARE (866-844-2273)
or 800-552-8338

Contact a UH Physician Liaison Team Member Direct

Transfer Referral Line

216-844-1111 or

UH Physician Portal

Request UH Physician Portal Access

Find a UH Facility